Miyachi H, Kiyota H, Segawa M
Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd., Tochigi, Japan.
Bioorg Med Chem Lett. 1998 Aug 18;8(16):2163-8. doi: 10.1016/s0960-894x(98)00393-x.
A series of 4-(2-methylimidazol-1-yl)-2,2-diphenylbutyramide derivatives was prepared as part of a search for subtype-selective antimuscarinic agents. On the basis of measurements of the antimuscarinic activity and subtype-selectivity for M2 and M3 muscarinic receptors, the structure-activity relationships of these compounds are discussed.